By Ethan Covey
An outbreak of bloodstream infections (BSIs) that affected people in three states has been traced to the use of non–FDA-approved umbilical cord–derived stem cell products.
Currently, stem cell products, which are derived from umbilical cord blood, are indicated only for use in hematopoietic and immunologic reconstitution. However, many clinics market stem cell products as treatment for various uses, such as orthopedic, neurologic and rheumatologic conditions, which are